000024387 000__ 01335cam\a2200373\i\4500
000024387 001__ 24387
000024387 003__ SzGeWIPO
000024387 005__ 20240708162236.0
000024387 008__ 080201s2008    enk|||||r|||| 00| 0 fre d
000024387 035__ $$a(wipo)0
000024387 035__ $$a(OCoLC)1160959483
000024387 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000024387 050_4 $$aK9$$b.N7477
000024387 08204 $$a346.04805$$219
000024387 084__ $$a72$$qGB
000024387 24500 $$aLife Science Focus.
000024387 264_1 $$aLondon [England] :$$bEuromoney Institutional Investor PLC,$$c2008.
000024387 300__ $$a1 volume ([1] page) ;$$c[28] cm.
000024387 336__ $$atext$$btxt$$2rdacontent
000024387 337__ $$aunmediated$$bn$$2rdamedia
000024387 338__ $$avolume$$bnc$$2rdacarrier
000024387 4901_ $$aManaging Intellectual Property,$$x0824-7064 ;$$vGB 72 Apr 2008 No 178, pages 61 - 68
000024387 500__ $$aManaging IP's dedicated bi-monthly industry report.
000024387 650_0 $$aIntellectual property$$zCanada.
000024387 650_0 $$aCopyright.
000024387 650_0 $$aIntellectual property.
000024387 650_4 $$aLife Science$$xPharmaceutical Industry
000024387 650_4 $$aUSPTO$$xPatents
000024387 650_6 $$aPropriété intellectuelle.
000024387 830_0 $$aManaging Intellectual Property ;$$vGB 72 Apr 2008 No 178, pages 61 - 68.
000024387 903__ $$aManaging Intellectual Property.
000024387 904__ $$aJournal article
000024387 942__ $$cART$$jGB 72 February 2008 No 176$$2ddc
000024387 952__ $$w2008-06-18$$p2008-0408$$u38057$$bMAIN$$10$$kGB 72$$v2008-06-18$$zLibrary$$70$$cMain Library
000024387 980__ $$aBIB
000024387 999__ $$c26660$$d26660